Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy

Next Previous
X
Search
Trial Profile

A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Churg-Strauss syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms MIRRA
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 14 Nov 2022 Results of post hoc analysis assessing efficacy of mepolizumab in patients with a vasculitic phenotype, presented at the ACR Convergence 2022.
    • 04 Jun 2022 Results assessing efficacy of mepolizumab in patients with a vasculitic EGPA phenotype , presented at the 23rd Annual Congress of the European League Against Rheumatism.
    • 28 Feb 2022 Using data from this study impact of baseline treatment, disease duration, and refractory status on mepolizumab efficacy has been investigated presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top